The IPO was 25c for 89,840,000 shares That means the company was...

First 14 Last

Share
Profile

Follow
kickit2me

13,624 Posts.

4845

23/07/21

15:07

Post #: 54725499
Share

Originally posted by stonks-1: ↑

IMO, following the share placement in June and subsequent share dilution there has definitely been a marked decrease in investor sentiment, which I think is understandable. However, given the well structured plan for the newly raised capital, namely and most importantly the purchase of the 5G spectrum and 5G network conversion as well as the strong potential of the NVIDIA GeForce NOW cloud gaming service, I still feel confident in the long term potential of this stock.

My confidence in Pentanet primarily stems from the Pentanet Fixed Wireless offering. Considering the rather poor performance of the new National Broadband Network (NBN) rollout and rise of 4K streaming, smart homes, WFH practises, video conferencing, etc, the demand and need for high-speed internet will only continue to increase and these demands cannot adequately be met by NBN. Let me tell you why... In Australia particularly, we are faced with a strong geographical and physical boundary when considering network and telecommunications, mostly due to the sheer size of this country. I know that in certain countries, they are able to upgrade their internet cables 2-3 times a decade but this simply isn't viable in Australia from a logistical and financial perspective. Therefore, I believe that technologies such as the Fixed Wireless - which essentially places a small dish on a roof and creates a wireless link to the telecommunications tower - are the future for Internet, especially in Australia. I believe that the main concern here will be competitor companies (i.e. Starlink) but here in Perth at least, customer support and sentiment for Pentanet is positive and rather loyal.

I got in on this share @ 61.5c and only now am starting to be in the red. If the price continues to drop I will look to top up and lower my average price. Definitely a long term holding for myself.

Expand

The IPO was 25c for 89,840,000 shares

That means the company was valued at that point ( 29th January ) at $22.46m.

While I also think the Fixed Wireless network has great potential, and great margins, can you suggest why the company is now being valued by the market at $176.8m?

I certainly can't hence, took my profits and am just going to sit back and watch until the market cap comes down to what fait value might be.

...

5GG Price at posting: 58.5¢ Sentiment: Sell Disclosure: Not Held
1 Upvote

0 Great analysis

Reply

Top Stories

CHM

Leukaemia patient shows complete response in Chimeric Therapeutics' latest trial

RCE

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

NEU

Neuren sees FDA greenlight for 3rd trial into children with Phelan-McDermid syndrome

Arika to pump $3.2M into gold exploration at WA's Yundamindra following strong maiden program

NYR

Nyrada rat study shows no genotoxicity in brain injury drug NYR-BI03

There are more pages in this discussion • 3 more messages in this thread...

First 14 Last

Add 5GG (ASX) to my watchlist

(20min delay)
Last 3.3¢		Change 0.000(0.00%)		Mkt cap ! $14.72M

Open	High	Low	Value	Volume
3.4¢	3.5¢	3.3¢	$3.189K	94.75K

Buyers (Bids)

No.	Vol.	Price($)
1	19164	3.3¢

Sellers (Offers)

Price($)	Vol.	No.
3.4¢	9440	1

View Market Depth

No.	Vol.	Price($)
1	19164	0.033
5	588750	0.032
2	116129	0.031
4	260719	0.030
1	7586	0.029

Price($)	Vol.	No.
0.034	9440	1
0.035	88734	3
0.036	828140	3
0.037	41295	1
0.040	275500	3

Last trade - 14.22pm 07/10/2024 (20 minute delay)

5GG (ASX) Chart

The IPO was 25c for 89,840,000 shares That means the company was...

Leukaemia patient shows complete response in Chimeric Therapeutics' latest trial

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

Neuren sees FDA greenlight for 3rd trial into children with Phelan-McDermid syndrome

Arika to pump $3.2M into gold exploration at WA's Yundamindra following strong maiden program

Nyrada rat study shows no genotoxicity in brain injury drug NYR-BI03

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

The IPO was 25c for 89,840,000 shares That means the company was...

Top Stories

Leukaemia patient shows complete response in Chimeric Therapeutics' latest trial

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

Neuren sees FDA greenlight for 3rd trial into children with Phelan-McDermid syndrome

Arika to pump $3.2M into gold exploration at WA's Yundamindra following strong maiden program

Nyrada rat study shows no genotoxicity in brain injury drug NYR-BI03

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News